NAD+ Program
Provider-tailored NAD+ delivery pathway focused on cellular energy and repair support.
Physician-supervised NAD+, Sermorelin, and B12 MIC protocols designed for cellular energy, sleep architecture, recovery, and long-horizon healthspan support.
Early access list — 30% off your first 3 months when we launch:
NAD+ levels can fall significantly from youth baseline by midlife.
Program pricing targets lower monthly cost than common drip-spa alternatives.
Longevity demand continues to scale as consumer awareness rises.
Sleep, nutrition, stress, biomarkers, and sustainable protocol adherence.
NAD+ sits at the center of ATP production and DNA repair signaling. Combined with peptide-guided recovery support, the goal is to improve resilience and recovery capacity over time.
Patients commonly report improvements in sustained energy, mental clarity, and recovery consistency over early treatment phases.
It is used for pituitary-mediated growth hormone signaling support and is often discussed around sleep and recovery quality goals.
NAD+ and peptide pathways are often paired so the provider can target energy, sleep quality, and tissue recovery in one plan.
NAD+, Sermorelin, and combined stacking options with provider-supervised dosing and coaching support.
Provider-tailored NAD+ delivery pathway focused on cellular energy and repair support.
Provider-supervised peptide pathway commonly used for sleep and recovery optimization goals.
Combined energy and recovery pathway for patients seeking the fullest longevity support stack.
Methionine, Inositol, Choline, and B12 support pathway commonly paired with longevity and metabolic protocols.
Join the early access list now. Launch users are prioritized and receive introductory pricing.
Injection is the most established delivery route with direct systemic absorption. Oral dropper is non-injection and convenience-focused. Your provider chooses the route based on goals and adherence fit.
No. Sermorelin stimulates natural growth-hormone signaling through the pituitary pathway rather than replacing hormone directly. The treatment decision is provider-led and individualized.
Yes, when clinically appropriate. The care team can design a combined plan for maintenance and healthspan support after or during GLP-1 phases.
It is presented as a coming-soon program with early access notifications sent first to waitlist users and existing active members.